Delving into the Latest Updates on Curelong (Beijing) Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Congenital Disorders

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Immune System Diseases	1
Endocrinology and Metabolic Disease	1
Infectious Diseases	1
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

Top II(Topoisomerase II)	1

主要目的： 1、在经标准治疗失败（疾病进展或无法耐受）或缺乏标准治疗的晚期实体肿瘤患者中确定注射用盐酸多柔比星胶束高剂量组的安全性。次要目的： 1、探索注射用盐酸多柔比星胶束单药在晚期实体肿瘤患者中的药代动力学（PK）特征； 2、初步评价注射用盐酸多柔比星胶束高剂量组单药治疗晚期实体肿瘤的临床疗效； 3、与阳性药对照，比较二者的 PK 特征; 4、探索注射用盐酸多柔比星胶束的最大耐受剂量（MTD）。

[Translation]

Main objectives: 1. To determine the safety of high-dose doxorubicin hydrochloride micelles for injection in patients with advanced solid tumors who have failed standard treatment (disease progression or intolerance) or lack standard treatment. Secondary objectives: 1. To explore the pharmacokinetic (PK) characteristics of doxorubicin hydrochloride micelles for injection in patients with advanced solid tumors; 2. To preliminarily evaluate the clinical efficacy of high-dose doxorubicin hydrochloride micelles for injection in the treatment of advanced solid tumors; 3. To compare the PK characteristics of the two with positive drugs; 4. To explore the maximum tolerated dose (MTD) of doxorubicin hydrochloride micelles for injection.

Start Date09 Jul 2024

Sponsor / Collaborator

Institute of Biophysics of Chinese Academy of Sciences

[+1]

CTR20212752

/ RecruitingPhase 1

注射用盐酸多柔比星胶束治疗晚期实体肿瘤的Ia期临床研究

[Translation] Phase Ia clinical study of doxorubicin hydrochloride micelles for injection in the treatment of advanced solid tumors

主要目的：在经标准治疗失败（疾病进展或无法耐受）或缺乏标准治疗的晚期实体肿瘤患者中确定注射用盐酸多柔比星胶束的安全性、最大耐受剂量（MTD）或IIa期推荐剂量（RP2D）。次要目的：探索注射用盐酸多柔比星胶束单药在晚期实体肿瘤患者中的药代动力学（PK）特征；初步评价注射用盐酸多柔比星胶束单药治疗晚期实体肿瘤的临床疗效；与阳性药对照，比较二者的PK特征，并在剂量扩展阶段初步探索注射用盐酸多柔比星胶束单药治疗晚期乳腺癌、胃癌的临床优势。

[Translation]

Primary objective: To determine the safety, maximum tolerated dose (MTD) or Phase IIa recommended dose (RP2D) of doxorubicin hydrochloride micelles for injection in patients with advanced solid tumors who have failed standard treatment (disease progression or intolerance) or lack standard treatment. Secondary objective: To explore the pharmacokinetic (PK) characteristics of doxorubicin hydrochloride micelles for injection in patients with advanced solid tumors; To preliminarily evaluate the clinical efficacy of doxorubicin hydrochloride micelles for injection in the treatment of advanced solid tumors; To compare the PK characteristics of the two with the positive drug control, and to preliminarily explore the clinical advantages of doxorubicin hydrochloride micelles for injection in the treatment of advanced breast cancer and gastric cancer in the dose expansion phase.

Start Date22 Nov 2021

Sponsor / Collaborator

Institute of Biophysics of Chinese Academy of Sciences

[+1]

100 Clinical Results associated with Curelong (Beijing) Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Curelong (Beijing) Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Curelong (Beijing) Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Curelong (Beijing) Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 May 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data